Effective Implementation of good supplier quality assurance and industrial practices at a Pharmaceutical company.

This report has to be foccussed on reduction of rework and improvement of productivity by achieving zero or negligible error (eventually leading to FDA audit observations) through role of good supplier quality and industrial practices. When the facility is audited by FDA, it should not get any observations or 483s, because if it gets any observations then the whole project approval is jeopardized and it delays the NDA process which ultimately results in reluctant and unwanted expenditure of more time and money. So that is the main idea behind this report which should be addressed as the outcome of this report.